Association Between Neuropathic Pain and A-Waves in Leprosy Patients With Type 1 and 2 Reactions

2011 ◽  
Vol 28 (3) ◽  
pp. 329-332 ◽  
Author(s):  
José A. Garbino ◽  
Bernard Naafs ◽  
Manoel H. Salgado ◽  
Somei Ura ◽  
Marcos da C. L. Virmond ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Leprosy Patients

Sex Differences in Neuropathy and Neuropathic Pain in Long-Standing Diabetes—Results from the Canadian Study of Longevity in Type 1 Diabetes

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 560-P
Author(s):  
NANCY CARDINEZ ◽  
LEIF ERIK LOVBLOM ◽  
JOHNNY-WEI BAI ◽  
ALON ABRAHAM ◽  
EVAN J. LEWIS ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Sex Differences ◽  
Neuropathic Pain ◽  
Canadian Study

Unusual non-trophic ulcerations in leprosy: A case series of 17 patients

2021 ◽  
pp. 004947552199849
Author(s):  
Prakriti Shukla ◽  
Kiran Preet Malhotra ◽  
Parul Verma ◽  
Swastika Suvirya ◽  
Abir Saraswat ◽  
...  
Keyword(s):  
Erythema Nodosum ◽  
Case Series ◽  
Lepromatous Leprosy ◽  
Sweet Syndrome ◽  
Erythema Nodosum Leprosum ◽  
Leprosy Patients ◽  
Atypical Presentations ◽  
Neuropathic Ulcers

Non-neuropathic ulcers in leprosy patients are infrequently seen, and atypical presentations are prone to misdiagnosis. We evaluated diagnosed cases of leprosy between January 2017 and January 2020 for the presence of cutaneous ulceration, Ridley–Jopling subtype of leprosy, reactions and histologic features of these ulcerations. Treatment was given as WHO recommended multi-bacillary multi-drug therapy. We found 17/386 leprosy patients with non-neuropathic ulcers. We describe three causes – spontaneous cutaneous ulceration in lepromatous leprosy (one nodular and one diffuse), lepra reactions (five patients with type 1; nine with type 2, further categorised into ulcerated Sweet syndrome-like who also had pseudoepitheliomatous hyperplasia, pustulo-necrotic and necrotic erythema nodosum leprosum) and Lucio phenomenon (one patient). Our series draws attention towards the different faces of non-neuropathic ulcers in leprosy, including some atypical and novel presentations.

Risk factors for type-1 reactions in borderline leprosy patients

The Lancet ◽  
1991 ◽  
Vol 338 (8768) ◽  
pp. 654-657 ◽  
Author(s):  
P.W. Roche ◽  
W.J. Theuvenet ◽  
W.J. Britton
Keyword(s):  
Risk Factors ◽  
Leprosy Patients

Alteration of the cortisol–cortisone shuttle in leprosy type 1 reactions in leprosy patients in Hyderabad, India

2007 ◽  
Vol 109 (1) ◽  
pp. 72-75 ◽  
Author(s):  
Anna K. Andersson ◽  
Sara E. Atkinson ◽  
Saroj Khanolkar-Young ◽  
MeherVani Chaduvula ◽  
Suman Jain ◽  
...  
Keyword(s):  
Leprosy Patients

scholarly journals A randomized clinical trial of oral steroids for ulnar neuropathy in type 1 and type 2 leprosy reactions

2008 ◽  
Vol 66 (4) ◽  
pp. 861-867 ◽  
Author(s):  
José Antonio Garbino ◽  
Marcos da Cunha Lopes Virmond ◽  
Somei Ura ◽  
Manoel Henrique Salgado ◽  
Bernard Naafs
Keyword(s):  
Motor Nerve ◽  
Clinical Score ◽  
Ulnar Neuropathy ◽  
Control Group ◽  
Spontaneous Pain ◽  
Oral Steroids ◽  
Leprosy Patients ◽  
Higher Doses

BACKGROUND: Steroids regimens in leprosy neuropathies are still controversial in botth types of reactions. METHOD: For this trial, 21 patients with ulnar neuropathy were selected from 163 leprosy patients, 12 with type 1 reaction (T1R) and nine with type 2 (T2R). One experimental group started with prednisone 2 mg/kg/day and the control group with 1 mg/kg/day. A clinical score based on tests for spontaneous pain, nerve palpation, sensory and muscle function was used. Neurophysiological evaluation consisted on the motor nerve conduction of the ulnar nerve in three segments. Student "t" test for statistical analysis was applied on the results: before treatment, first week, first month and sixth month, between each regimen and types of reaction. CONCLUSION: In both reactions during the first month higher doses of steroids produced better results but, earlier treatment with lower dose was as effective. Short periods of steroid, 1 mg/Kg/day at the beginning and,tapering to 0,5 mg/Kg/day or less in one month turned out to be efficient in T2R.

260 PREVALENCE OF POLYNEUROPATHY WITH OR WITHOUT NEUROPATHIC PAIN IN TYPE 1 AND 2 DIABETIC PATIENTS

2007 ◽  
Vol 11 (S1) ◽  
pp. S115-S115 ◽  
Author(s):  
D. Bouhassira ◽  
K. Acker ◽  
S. Weiss ◽  
K. Matthys ◽  
C. Mathieu ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Diabetic Patients

Analysis of the Myeloid-Derived Suppressor Cells and Annexin A1 in Multibacillary Leprosy and Reactional Episodes

2020 ◽  
Author(s):  
Amilcar Sabino Damazo ◽  
Stephanni Figueiredo da Silva ◽  
Leticia Rossetto da Silva Cavalcante ◽  
Ezequiel Angelo Fonseca Junior ◽  
Joselina Maria da Silva ◽  
...  
Keyword(s):  
Suppressor Cells ◽  
Suppressor Cell ◽  
Mycobacterium Leprae ◽  
Histopathological Analysis ◽  
Annexin A1 ◽  
Myeloid Derived Suppressor Cells ◽  
Myeloid Derived Suppressor Cell ◽  
Leprosy Patients ◽  
Multibacillary Leprosy

Abstract Background: Leprosy is a chronic infectious disease caused by Mycobacterium leprae. Patients have distinct clinical forms, and host´s immunological response regulate those manifestations. In this work, the presence of the myeloid-derived suppressor cell and the regulatory protein annexin A1 is described in patients with multibacillary leprosy and with type 1 and 2 reactions. Methods: Patients were submitted to skin biopsy for histopathological analysis to obtain bacilloscopic index. Immunofluorescence was used to detect myeloid-derived suppressor cells and annexin A1.Results: The data demonstrated that the presence of granulocytic and monocytic myeloid-derived suppressor cells in leprosy patients. The high number of monocytic myeloid-derived suppressor cells were observed in lepromatous leprosy and type 2 reactional patients with Bacillus Calmette–Guérin (BCG) vaccination scar. The presence of annexin A1 was observed in all myeloid-derived suppressor cells. In particularly, the monocytic myeloid-derived suppressor cell in the lepromatous patients has higher levels of this protein when compared to the reactional patients. This data suggest that the higher expression of this protein may be related to regulatory response against a severe infection, contributing to anergic response. In type 1 reactional patients, the expression of annexin A1 was reduced. Conclusions: Myeloid-derived suppressor cell are present in leprosy patients and annexin A1 might be regulated the host response against Mycobacterium leprae.

Sign in / Sign up

Export Citation Format

Share Document